Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
De Jaeghere EA, Tuyaerts S, Van Nufel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG. De Jaeghere EA, et al. Among authors: de caluwe a. Cancer Immunol Immunother. 2024 Dec 30;74(1):32. doi: 10.1007/s00262-024-03873-5. Cancer Immunol Immunother. 2024. PMID: 39738642 Free PMC article. No abstract available.
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG. De Jaeghere EA, et al. Among authors: de caluwe a, de wever o. Cancer Immunol Immunother. 2023 Feb;72(2):475-491. doi: 10.1007/s00262-022-03253-x. Epub 2022 Aug 12. Cancer Immunol Immunother. 2023. PMID: 35960332 Free PMC article. Clinical Trial.
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H. Tuyaerts S, et al. Among authors: de caluwe a, de jaeghere e. BMC Cancer. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3. BMC Cancer. 2019. PMID: 31138229 Free PMC article. Clinical Trial.
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
De Jaeghere EA, Hamerlinck H, Tuyaerts S, Lippens L, Van Nuffel AMT, Baiden-Amissah R, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Verhasselt B, Denys HG. De Jaeghere EA, et al. Among authors: de caluwe a. Gynecol Oncol. 2024 Dec;191:275-286. doi: 10.1016/j.ygyno.2024.10.020. Epub 2024 Nov 7. Gynecol Oncol. 2024. PMID: 39515198 Clinical Trial.
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
De Caluwe A, Romano E, Poortmans P, Gombos A, Agostinetto E, Marta GN, Denis Z, Drisis S, Vandekerkhove C, Desmet A, Philippson C, Craciun L, Veys I, Larsimont D, Paesmans M, Van Gestel D, Salgado R, Sotiriou C, Piccart-Gebhart M, Ignatiadis M, Buisseret L. De Caluwe A, et al. J Immunother Cancer. 2023 Dec 6;11(12):e007279. doi: 10.1136/jitc-2023-007279. J Immunother Cancer. 2023. PMID: 38056900 Free PMC article. Clinical Trial.
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
De Caluwé A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Stylianos D, Vandekerckhove C, Reyal F, Isabelle V, Eiger D, Piccart M, Romano E, Ignatiadis M. De Caluwé A, et al. BMC Cancer. 2021 Aug 6;21(1):899. doi: 10.1186/s12885-021-08601-1. BMC Cancer. 2021. PMID: 34362344 Free PMC article.
Delineation guidelines for the lymphatic target volumes in 'prone crawl' radiotherapy treatment position for breast cancer patients.
Stouthandel MEJ, Kayser F, Vakaet V, Khoury R, Deseyne P, Monten C, Schoepen M, Remouchamps V, De Caluwé A, Janoray G, De Neve W, Mazy S, Veldeman L, Van Hoof T. Stouthandel MEJ, et al. Among authors: de caluwe a, de neve w. Sci Rep. 2021 Nov 18;11(1):22529. doi: 10.1038/s41598-021-01841-y. Sci Rep. 2021. PMID: 34795352 Free PMC article.
27 results